WILMINGTON, Del. - TelAve -- Biophysical Therapeutics, a Delaware company, announces the launch of its consumer longevity brand called IF1.

It is currently accepting pre-orders for its first product, an anti-aging skin moisturizer available at www.IF1.skin. Only 500 units are available in the initial production run, retailing at $120 apiece.

This moisturizer is distinctive in incorporating leading-edge longevity science, and is further distinct, since the profit from its sales will feed back to fund the company's drug programs, which include drugs against cancer, age-related diseases (such as Alzheimer's disease), and aging itself.

The company was founded in 2022 by Dr. Michael Forrest, a Cambridge University biochemistry graduate with a Ph.D. in computer science, and is advised by Professor George Church of Harvard Medical School. Its specialty is computational biology and especially biophysical modeling, which is mathematical modeling of the physics and chemistry of a biological system, and the company is named after this approach. Unusually for a computational biology company, it has actually delivered new experimentally-validated drugs working as predicted in vivo, protected by granted patents.

More on TelAve News

• Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
• Building Smarter Networks with Cloud-Native Technology
• Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
• Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
• Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories

The science behind the company's new anti-aging skin moisturizer is its conclusion regarding why different mammal species can have such different lifespans, for example, a mouse maximally lives 4 years whereas a bowhead whale can live centuries longer. This conclusion is complex but it distills to simplicity - species with more IF1 protein live longer. Indeed, the company has shown that increasing IF1 protein in mice reduces aging as measured by an aging biomarker.

People already buy anti-aging skincare. Indeed, it is already a $70B market and growing. This bodes well for this new brand that leverages differentiated anti-aging science from leading anti-aging scientists, which will in turn fund them to advance science and medicine. Economists calculate that the economic benefit of slower aging, to the USA alone, is $38T per year of increased life expectancy.

Dr. Forrest says: "Our IF1 brand brings leading-edge anti-aging science to skincare. This is just part of our mission to save, improve, and extend lives at mass scale."

More on TelAve News

• Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
• ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
• Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
• Revenue Optics Names Prat Patibandla Director of Growth Marketing
• Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions

The IF1 anti-aging skin moisturizer is available for pre-order now exclusively at www.IF1.skin.

About Biophysical Therapeutics
Biophysical Therapeutics is a Delaware-based biotechnology company that uses computational biology, especially biophysical modeling, to discover new fundamental biology and design new drugs. Its primary targets are cancer, the diseases of aging (e.g., Alzheimer's disease), and aging itself. The company has a pipeline of experimentally-validated new drugs and a portfolio of granted patents. It owns a longevity skincare brand called IF1, which is available at www.IF1.skin.